EIKN vs QDEL: fair value comparison
Eikon Therapeutics, Inc. and QuidelOrtho Corporation · Updated 2026-10-19
EIKN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, QDEL currently ranks higher by quality score.
| EIKN | QDEL | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $7.42 | $12.91 |
| 12-month range | $7.41–$15.00 | $9.96–$35.38 |
| Rank by discount to fair value | — | #101 of 108 Healthcare |
| Rank by quality score | #287 of 301 Healthcare | #286 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | High |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: EIKN fair value analysis · QDEL fair value analysis